Documenti di Didattica
Documenti di Professioni
Documenti di Cultura
stand
position in new drug development. Deregulation
and streamlined new drug approval processes are
attracting increased foreign investments;
Organised by:
268
Positions - Pharmaceutical manufacturing/
Pharmaceutical contract manufacturing
235
20% Research
103
14% Development
17% Others
18% Research
28% Pharmaceutical manufacturing/
43 % Others
Pharmaceutical contract 14% Development
manufacturing
10% Management
6% Purchasing / Procurement
6% Business Development
38% Others
104.203
16.8%
102.059
US$bn
in Sales
10 Volume-based 100
99.951
98.659
8.8% Money-based
7.6%
96.555
5 6.6%
5.9%
95
2015 2016 2017 2018 2019
0
Reference: BMI
Reference: The Ministry of Health,
2005 2007 2009 2011 Labour and Welfare Report 2013
Ageing population
Entering the next stage as a global
hub for drug development Japan's ageing population will further drive demand
for pharmaceutical products. By 2024, the pensionable
Japan has joined the Pharmaceutical population as a percentage of the total will grow to
30.7%, up from 25.8% in 2014.
Inspection Convention and Pharmaceutical
Inspection Cooperation Scheme (PIC/S). This
enables overseas suppliers to synchronise
Liberisation of Over-The-Counter
with Japanese pharmaceutical manufacturers
regarding manufacturing and quality control. medicines
In addition, Japans pharmaceutical industry The liberalisation of Over-The-Counter medicines and
will become more international as well as the allowance of sales of over-the-counter (OTC) drugs
easier for foreign suppliers to enter the online serve to boost pharmaceutical sales. 99.8% of
OTC drugs are now eligible for sale online (more than
Japanese market! 11,000 drugs).
7
leading international and domestic pharmaceutical companies and %
prestigious universities.
welcome to participate FREE of charge!
CPhI Online CPhI Japan is great to meet and network with existing
Enhance online exposure of your company and products on CPhI and new partners in the pharma industry. We barely had
Online. Stay connected with buyers before and after the show.
With 32,000+ unique visitors per month, CPhI Online is a pharma
sourcing directory that allows you to:
time to breathe during the three days and the quality of
the meetings were excellent. We look forward to next
Generate leads years show!
Increase brand awareness
Stay updated on pharma industry news and trends Silke Oeschger
Marketing and Communications Manager
Dr. Reddys Laboratories Ltd.
Organised by:
Show name
CPhI Japan 2016
ICSE Japan 2016
P-MEC Japan 2016
BioPh Japan 2016
InnoPack Japan 2016
7,790 in 2015 26
7,028 visitors
20 April,Wednesday Countries:
China 185 United Kingdom 8 Belarus 1 Portugal 1
21 April,Thursday6,261 in 2015
5,034 visitors
Japan 165 Spain 7 Denmark 1 Singapore 1
India 46 Switzerland 7 Hungary 1 Sweden 1
South Korea 26 Taiwan 6 Israel 1 Turkey 1
5,630 in 2015
4,122 visitors
Italy 16 France 4 Latvia 1 Ukraine 1
22 April,Friday USA 16 Russian Federation 3 Lithuania 1
Germany 9 Finland 2 Poland 1
JAPAN LIFE SCIENCE WEEK
Health Care I T
Tokyo Big Sight
East Hall Pavilion:
40exhibito rs 140,99visitors Main Entrance 456
Japan Bulk Pharmaceutical
Manufacturers pavilion
East Hall
123 Pharmaceutical Excipients pavilion
FREE
China pavilion
ACCESS Korea pavilion
UK pavilion
India pavilion
Italy pavilion
Spain pavilion
Pharmaceutical Industry Medical Equipment Industry
Organised by:
CPhI / ICSE / P-MEC / BioPh / InnoPackJapan 2016Fact & Figures
TOP 5
Consolidating International
contacts 14 countries
CHINA
KOREA
Attending TAIWAN
conference 16
INDIA
USA
Collecting market / product
information 30%
Book your stand for unrivalled access to the Japanese Pharma market!!
CPhI Japan 2017 ICSE Japan 2017 P-MEC Japan 2017 BioPh Japan 2017 InnoPack Japan 2017
ICSE Japan connects the pharmaceutical community with diverse outsourcing solutions such as:
clinical trials, contract manufacturing, contract research, packaging, logistics or analytical
services. Find a broad range of products with the latest developments and meet the company
representatives in person.
Exhibitors include:
Contract Research Marketing Services
Japan is one of the countries that dominates the global pharmaceutical packaging market.
Moreover, it is the world's second largest pharma market and also the largest pharmaceutical
packaging market within the Asia-Pacific region.
* Primary packaging: ampoule, vial, bottle cartridge, syringe, reconstitution system, sprays,
pumps, aerosols, medical packaging, unit doses, I.V. pouches, tubes, caps and many more
* Secondary packaging (i.e. medical packaging, wallet)
* Design, creation and production of drug delivery devices
* Development and packaging services
* Raw Materials (aluminium, cardboard, plastic, advanced polymers, rubber and glass)
* Films and semi-finished packaging materials (incl. blister packaging)
* Syringes and pre-filled syringe components (i.e. plungers, needle shields, tip caps, stoppers)
* Drug delivery devices/systems (i.e. inhalator, DPI, pen injector)
* Automation and assembly systems
* Manufacturers of transdermal systems and associated technology
* Folding cartons, labelling, printing, anti-counterfeit and tracing technologies
* Testing
Interested?
Join these exhibitors and many more in networking with our international visitors and benefit from
the thriving pharmaceutical market and opportunity this unique business platform and the co-
located events offer. For more information on how to exhibit at InnoPack Japan please contact
Mr. Vikram Rao at +31 20 40 99 524 or send an email to vikram.rao@ubm.com.
P-MEC Japan
P-MEC Japan is the opportunity to showcase innovative
pharmaceutical machinery, laboratory equipment and analytical
technology for API and Intermediates through face to face
networking and education.
Japan's medical device market is projected to expand at a Compounded Annual Growth Rate of
2.5% in between 2013 and 2018. The market is estimated to grow to around US$33.6bn in 2018.
Japan is one of the world's most technological advanced countries. Japan's APIs, intermediates
producers and pharmaceutical manufacturers are always on the lookout for new technologies in
quality control, safety assurance and increasing production efficiency. The requirements of
Japanese companies are possibly the highest in the world; if you are a supplier of competitive
products in these three fields, Japan is the market for you.
Following its successful previous editions, P-MEC Japan, the Pharmaceutical Machinery and
Equipment Convention, will once again provide you with an excellent opportunity to
present your advanced technologies to the most sophisticated market in Asia!
Visitor job sections at P-MEC Japan 2015 included*:
* Analyzer
* Synthesizer
* Chromatography
* Concentration System
* Centrifugal Separators
* Reaction Vessels
* Filtration Devices
* Granulators
* Agitators
* Dryers
Interested?
Join these exhibitors and many more in networking with our international visitors and benefit from
the thriving pharmaceutical market and opportunity this unique business platform and the co-
located events offer. For more information on how to exhibit at P-MEC Japan | LABWorld
Japan 2016, please contact Mr. Vikram Rao at +31 (0) 20 40 99 524 or send an email
to vikram.rao@ubm.com
BioPh Japan
BioPh Japan, focusing on biopharmaceutical development and services,
brings bio solutions to CPhI Japan and is for companies and organisations involved in the
research and development of new treatment methods arising from biotechnical processes or
which are derived from, or use live organisms.
Structural economic reforms in Japan have fuelled a continued rally in biotechnology. The
Japanese pharmaceutical manufacturers have been eager to catch up the US and European
players in the bio field by investing and cooperating with bio ventures & universities.
The government has also been investing in infrastructure development such as bio industrial
cluster projects and setting up support programs for bio ventures & universities in order to
enhance Japan's bio pharma industry.
The markets for biologics such as antibodies, protein based drugs and vaccines
have been increasing. Biotechnology-based drugs are anticipated to be one of the key drivers of
the pharmaceutical market and this is reflected in the growing number biotechnology based
drugs among newly approved medicines.
If you are dealing with the research and development of new treatment methods made through
biotechnological processes or which are derived from or use live organisms or a supplier of bio
pharma raw materials, services or equipment, don't miss this opportunity to benefit from the mix
of exhibition and seminars at BioPh.
Visitors at BioPh Japan 2015 showed interest* in:
Interested?
Join these exhibitors and many more in networking with our international visitors and benefit from
the thriving pharmaceutical market and opportunity this unique business platform and the co-
located events offer. For more information on how to exhibit at BioPh Japan please contact Mr.
Vikram Rao at +31 20 40 99 524 or send an email to vikram.rao@ubm.com
Press Release
22 April 2015
The growing importance of international cooperation within the industry has made the
CPhI Japan exhibition and its four parallel events - constituting the largest and most
international annual gathering of the pharmaceutical industry in Japan - an
indispensable opportunity for companies to meet new partners and forge new
relationships. Last year these five integrated pharma events attracted a
record-breaking17,000 visitors. This year there are 467 exhibiting companies from 27
countries and regions, and the exhibition will be the largest since its launch in 2002.
Exhibitors at CPhI Japan, ICSE Japan, P-MEC Japan, BioPh Japan and InnoPack
Japan 2015 by country:
Japan (179), China (126), India (42), South Korea (26), Italy (14), USA (12), UK (11),
Germany (9), Spain (9), Taiwan (8), Switzerland (7), France (5), Poland (2), Russian
Federation (2), San Marino (2), Sweden (2), Belarus (1), Denmark (1), Finland (1),
Hungary (1), Indonesia (1), Israel (1), Latvia (1), Lithuania (1), Portugal (1), Singapore
(1), Ukraine (1)
Total: 467 exhibitors from 27 countries & regions
Insight into Open Innovation Strategies of Japanese
Pharmaceutical Companies seminar to be held in cooperation
with the Japan Pharmaceutical Manufacturers Association
A reduction in the amount of time needed to evaluate new drugs for official approval in
Japan has led to foreign pharmaceutical manufacturers, who at one stage were closing
their research bases in Japan, to now reestablish R&D centers and increase their
investments. Meanwhile, the Japan Agency for Medical Research and Development
(AMED), a national research and development corporation, will be established in April
2015 to serve as a control tower for medical R&D activities, one of the main pillars of
Prime Minister Abes growth strategy. It is just one example of the trend in the Japanese
pharmaceutical industry is towards an improved environment for new drug
development.
With the tide of the industry running in this new direction, on April 24, the third day of
CPhI Japan, a seminar entitled Insight into Open Innovation Strategies of Japanese
Pharmaceutical Companies will be held on the theme of Encouragement of Innovation
for Quality Improvement of and Contribution to Economic Development by Medical
Care. The topic is one of the main themes of the activities of the Japan Pharmaceutical
Manufacturers Association (JPMA). Mr. Makoto Suematsu, the first president of the
Japan Agency for Medical Research and Development (AMED) will open the program
with an address. This will be followed by lectures by experts from Shionogi & Co., Ltd.,
Daiichi-Sankyo Co., Ltd., Astellas Pharma Inc., and Takeda Pharmaceutical Co., Ltd.,
who will provide insight into what their companies are doing in the pursuit of open
innovation.
Increased Use of Generic Drugs Leads to More API Suppliers
from China, India and Korea Exhibiting
With the development of new drugs becoming more active in Japan, one of the major
reasons for the increase in exhibit space at CPhI Japan must be the expansion of the
nations market for generic drugs.
A target of a 60% share for generic drugs, proposed in the April 2013 road map
announced by the Ministry of Public Health, Labour and Welfare, was attained earlier
than expected. This is but one example of the expanding trend of the generic drug
market. Meanwhile, the three major foreign groups of exhibitors including China, Korea
and India have significantly expanded their presence in this years exhibition.
Meanwhile from Europe, in addition to Spain exhibiting for the first time, Italy continues
to hold a steady position among active pharmaceutical ingredients (API) suppliers to
Japan and will expand the size of its pavilion this year. Foreign suppliers are clearly
expecting a new rise in API demand from Japan.
On the afternoon of April 22, the opening day of the exhibition, special presentations
under the title of The Future Vision of Generic Drugs - after 10 Years will be given by
Professor Masaki Muto, Representative Director of the Japan Society of Generic
Medicines, and Mr. Katsufumi Jo, Director of the Economic Affairs Division, Health
Policy Bureau, Ministry of Public Health, Labour and Welfare. They will discuss the
status of the generic drug market over the next ten years.
Initiative for Steady Supply of APIs to the Japanese Market
Along with the expansion of the market for generic pharmaceuticals, the role of foreign
suppliers of API is further increasing in importance. However, there are concerns that
the steady supply of API in the domestic market could become an issue. For example, if
GMP auditing resulted in a particular product being declared unacceptable, it would
result in the supply of the pertinent API being halted. Today, when such a situation
occurs, foreign API manufacturers are called upon to deepen their understanding of
Japanese GMP standards and the MF system. Japanese pharmaceutical
manufacturers, on the other hand, are urgently required to satisfy quality control
standards in Japan and secure access to price-competitive API suppliers.
To address these problems of API supply and quality control, last year an international
networking symposium entitled The Problem of Steady API Availability was launched
as a special event at CPhI Japan and attracted more than 600 participants. This years
edition will again bring together speakers from the Active Pharmaceutical Ingredients
Committee (APIC) of Europe, the Korea Pharmaceutical Traders Association (KPTA),
the China Chamber of Commerce for Import & Export of Medicines & Health Products
(CCCMHPIE) and the Pharmaceuticals and Medical Devices Agency (PMDA), an
independent administrative corporation, in Japan. The speakers are expected to put
forward proposals for problem solving regarding the steady supply of APIs from their
respective points of view.
Christopher Eve, President of UBM Japan, the organizer of the exhibition, comments:
Each year CPhI Japan has enjoyed the participation of many foreign governments and
trade associations, either as exhibitors or visitors. The stable supply of APIs a major
issue not only for generic drugs but also for new drugs and OTC drugs. I sincerely hope
that this seminar, organised by the Japan Pharmaceutical Traders Association, will
serve not only as an excellent opportunity for foreign API manufacturers to deepen their
understanding of GMP research and the MF system in Japan but also as a step toward
better mutual understanding between Japanese pharmaceutical manufacturers and the
world market.
More than 150 seminar sessions will be held alongside CPhI Japan this year. The
seminar program, which attracts over 8,000 persons from the industry, is an important
component of CPhI Japan. In addition to the seminars mentioned above, there will be
the Process Chemistry Seminar held in cooperation with the Japanese Society for
Process Chemistry on the themes of greater efficiency of manufacturing processes and
quality control. It will cover the full range of products from low to high molecular weight.
The Biopharma Seminar will focus on regenerative medicine, which is expected to bring
about a significant expansion of the market. In addition, the InnoPack Japan
Conference will discuss drug formulation technology, packaging technology and
proposals on pharmaceutical packaging technology from scenes of medical care
practice.
A keynote address will be delivered by Mr. Kazuhiko Mori, Director of the Evaluation
and Licensing Division, Pharmaceutical and Food Safety Bureau, Ministry of Public
Health, Labour and Welfare, who will discuss how to get away from the blockbuster
model and work out a new strategy for new drug development. Another keynote
address will be given by Mr. Masafumi Nogimori, President of the Federation of
Pharmaceutical Associations of Japan (concurrently Chairman of Astellas Pharma Inc.),
who will introduce the role of the Japanese pharmaceutical industry in realizing a
healthy and long life society under the title of Toward Sustainable Growth of
Pharmaceutical Industry.
InnoPack Japan 2015 DDS and Packaging Innovation debuts
Drug delivery systems (DDS) are the focus of attention for maximizing the effectiveness
of pharmaceuticals. The global market for DDS is estimated to be worth 15 trillion and
growing steadily. Pharmatec Japan, an exhibition serving the field of DDS and primary
packaging until last year, has now been renamed as InnoPack Japan / DDS and
Packaging Innovation for 2015, and has increased in display space.
According to the Ministry of Public Health, Labour and Welfare, one out of every six
Japanese citizens is a current or potential diabetes patient. With the demand for
self-injection insulin rising, this years InnoPack Japan will showcase the latest devices
on the market, including glass syringes, prefilled syringes and needles, by such major
Japanese syringe makers as NIPRO, Terumo and Taisei Kako, together with foreign
exhibitors such as Becton, Dickinson and Company and West Pharm.
This first edition of CPhI Women will feature a lecture entitled Designing Career
Options by Ms. Kuniko Shoji, Director and Senior Executive Officer, General Manager
of the Regulatory Affairs, Clinical Development Department, Terumo Corporation, who
will discuss some of the issues that women are likely to encounter in their work, and the
possible solutions. Following the lecture an informal networking exchange will be held.
Over 50 women from major Japanese pharmaceutical manufacturers will attend the
event.
India
holds
immense
growth
potential
and
the
market
is
poised
to
reach
sales
of
US$50bn
by
2020
(IMS
DATA),
up
from
US$21bn
in
2014.
On
the
other
hand
generic
build-up
and
contract
manufacturing
are
two
important
growth
modules
for
building
and
sustaining
the
Japan
pharmaceutical
Industry.
Japan
is
the
second
largest
pharmaceutical
market
but
is
still
a
relatively
unexplored
region
for
Indian
companies
when
compared
to
Europe
and
the
USA.
The
summits
objective
is
to
cultivate
Two-Way
Process
of
Business
&
Investment
between
the
nations.
The
motto
-
BRAND
INDIA
PHARMA
and
MAKE
IN
INDIA
-
will
be
unleashed
as
a
growth
strategy
and
opportunity
for
the
Japan
Pharmaceutical
and
HealthCare
sector.
The
summit
will
invite
representative
persons
from
the
Ministry
of
Commerce
of
the
Government
of
India,
Pharmexcil,
and
Indian
pharmaceutical
and
API
companies
as
speakers
to
talk
about
the
current
situation
of
Indias
pharmaceutical
industry
and
discuss
cooperation
between
Japan
and
India
in
developing
further
business
relationships
and
collaboration
by
inviting
guest
speakers
from
the
pharmaceutical
industry
in
Japan.
-ENDS-
About CPhI
CPhI drives growth and innovation at every step of the global pharmaceutical supply chain
from drug discovery to finished dosage. Through exhibitions, conferences and online
communities, CPhI brings together more than 100,000 pharmaceutical professionals each
year to network, identify business opportunities and expand the global market. CPhI hosts
events in Europe, China, India, Japan, Southeast Asia, Russia and South America and
co-locates with ICSE for contract services, P-MEC for machinery, equipment & technology,
BioPh for biopharma, and InnoPack for DDS and pharmaceutical packaging.